Drug intelligence / Profile preview

cisatracurium besylate + propofol + remifentanil + sevoflurane

Development stage
Phase 4
Lead developer
GSK
Modality
Small Molecules
Administration
Intravenous, Inhalation
01

Overview

This is a combination of four medications commonly used together in general anesthesia protocols: - **Cisatracurium besylate**: A non-depolarizing neuromuscular blocking agent (NMBA) with intermediate onset and duration of action. It is one of ten isomers of atracurium besylate (constituting approximately 15% of that mixture) and functions by blocking neuromuscular transmission at cholinergic receptors. It facilitates endotracheal intubation and provides skeletal muscle relaxation during surgery or mechanical ventilation. - **Propofol**: An intravenous anesthetic agent used for induction and maintenance of general anesthesia. - **Remifentanil**: A potent, short-acting synthetic opioid analgesic used during general anesthesia for pain control. - **Sevoflurane**: An inhalational anesthetic agent used for induction and maintenance of general anesthesia. This combination provides complete general anesthesia with hypnosis (propofol, sevoflurane), analgesia (remifentanil), and muscle relaxation (cisatracurium).

Brand names
Nimbex (for cisatracurium besylate component)
02

Targets

GABRR (GABA-A receptor subunit rho)Muscle-type nicotinic acetylcholine receptorMOR (Mu opioid receptor)

Beyond the preview

Go deeper on cisatracurium besylate + propofol + remifentanil + sevoflurane.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cisatracurium besylate + propofol + remifentanil + sevoflurane.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call